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Awell defined structure is available for the carboxyl half of the cellular prion protein (PrPc), while the structure of the amino terminal half of
the molecule remains ill defined. The unstructured nature of the polypeptide has meant that relatively few of the many antibodies generated against
PrPc recognise this region. To circumvent this problem, we have used a previously characterised and well expressed fragment derived from the
amino terminus of PrPc as bait for panning a single chain antibody phage (scFv-P) library. Using this approach, we identified and characterised 1
predominant and 3 additional scFv-Ps that contained different VH and VL sequences and that bound specifically to the PrP
c target. Epitope
mapping revealed that all scFv-Ps recognised linear epitopes between PrPc residues 76 and 156. When compared with existing monoclonal
antibodies (MAb), the binding of the scFvs was significantly different in that high level binding was evident on truncated forms of PrPc that
reacted poorly or not at all with several pre-existing MAbs. These data suggest that the isolated scFv-Ps bind to novel epitopes within the amino-
central region of PrPc. In addition, the binding of MAbs to known linear epitopes within PrPc depends strongly on the endpoints of the target PrPc
fragment used.
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The cellular prion protein (PrPc) plays a predominant role in
the sporadic, inherited and transmissible spongiform encepha-
lopathies (Horwich and Weissman, 1997; Liemann and
Glockshuber, 1998; Prusiner and Scott, 1997). Disease is
associated with an alteration in protein conformation to a form
characterised by aggregation and resistance to proteolytic
degradation, the Scrapie isoform PrPSc. The prion protein, a
mature extracellular polypeptide of 231 amino acids, has a
unique polypeptide sequence with a well defined and extremely
stable C-terminal domain, residues 120–231, for which several
NMR structures are available (Calzolai et al., 2000; Donne et
al., 1997; Riek et al., 1996; Zahn et al., 2000) and a flexible⁎ Corresponding author. Fax: +44 118 378 8902.
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doi:10.1016/j.virol.2006.08.023disordered amino terminal domain. Although structurally
uncertain, the N-terminal half of the protein contains a number
of conserved sequence features related to biological activity,
including the octarepeats, residues 51–90, known to bind metal
ions (Brown et al., 1997; Kramer et al., 2001; Perera and
Hooper, 2001; Stockel et al., 1998; Wong et al., 2000), a
hydrophobic stretch of residues, 106–126, that cause activation
of selected kinases (Gavin et al., 2005) and PrPc dependent
neurotoxicity in isolation (Forloni et al., 1993; Jobling et al.,
2001) and residues critical to the conversion to PrPSc (Flechsig
et al., 2000; Leclerc et al., 2001; Peretz et al., 2002).
As a complete prion protein structure is unavailable,
antibodies (Ab) to the prion protein are of interest as probes
of the native and disease conformations of the protein. Those
with selectivity for the latter may have a role also in antemortem
diagnostic tests for PrP disease (Korth et al., 1997; Paramithiotis
et al., 2003). Antibodies may also have therapeutic potential
(Donofrio et al., 2005; Peretz et al., 2001, 2004; White et al.,
2003) and, through binding, illustrate the signalling properties
of PrPc (Solforosi et al., 2004). When used as an immunogen,
167C.S. Adamson et al. / Virology 358 (2007) 166–177the predominant polyvalent response to PrPc protein is almost
wholly against the stable C-terminal fragment (Rubenstein et
al., 1999; Sachsamanoglou et al., 2004). Similarly, the
generation of monoclonal antibodies (MAb) has generally
given rise to many C-terminal or conformational antibodies
(Demart et al., 1999). Of 10 groups of dedicated anti-PrPc
MAbs reported recently, only one group was identified within
the N-terminus of the protein (Kim et al., 2004). By contrast,
phage display has generated a larger range of antibodies or
single chain antibody fragments (scFv), some of which have
been able to distinguish prion strains and the conformational
changes around residues 90–120 that are thought to precede or
accompany the generation of the disease isoform (Novitskaya et
al., 2006; Peretz et al., 1997, 2002). Here we combine the phage
display approach to PrPc antibody isolation with an abundantly
expressed N-terminal fragment of PrPc encoding residues 29–
156 (Yao et al., 2003) to isolate further antibodies to this
innately flexible region. Antibodies isolated in this way have
significantly different binding properties when compared to
several existing monoclonals that map to similar regions of the
PrPc molecule.
Results
Isolation of antibodies specific to the N-terminal domain of
PrPc
To select scFv-Ps that specifically recognised the N-terminal
domain of PrPc, a recombinant fragment of PrPc representing
residues 29–156 was purified and used as bait antigen for
panning the Griffin.1 phage display library of human scFvs
(Griffiths et al., 1994). PrPc29–156 has a C-terminus coincident
with the end of the first helix within the known PrPc structure
(Riek et al., 1996), and an N-terminus at residue 29 following
the finding that expression beginning at the authentic mature N-
terminus, residues 23, was poor (Yao et al., 2003). Removal of
the amino terminal 6 basic residues however rescued high levelFig. 1. Source of bait antigen and scFv-Ps isolated. (A) A fragment of PrPc, PrPc29–156
described before use as bait antigen in panning reactions with the Griffin.1 human syn
the reaction after refolding and analysed by SDS-PAGE and Coomassie staining next
and light variable CDR3 scFv regions showing the diversity of the four antibodies cha
PrPc. The sequences were aligned using Vector NTI (InforMax).of expression (Yao et al., ibid). Expression of T7 promoter
driven PrPc29–156 in E. coli was highly efficient, and
recombinant protein was purified to ∼90% as inclusion bodies
and then denatured and refolded before use (Fig. 1A). After four
rounds of phage selection and enrichment, individual colonies
were picked and monoclonal phage stocks prepared. PrPc
positive binding clones were identified in an ELISA by their
ability to recognise baculovirus expressed PrPc29–156 fused to
GFP (Yao et al., 2003). Use of the insect cell expressed PrPc
fragment gave selectivity for clones specific for PrPc sequence
and avoided the low level (<10%) of contaminating proteins
associated with the refolded material derived from E. coli. Of
∼1000 clones screened, ∼10% showed specific recognition of
PrP29–156-GFP and DNA fingerprinting revealed 94% of this
population to be one dominant clone, CA22. A further three
clones with distinct fingerprints, CA328, CA330 and CA549,
were identified by exhaustive screening. Amplification of each
phagemid followed by DNA sequencing showed each clone to
have distinct heavy and light chains, although the light chains of
CA22 and CA328 were closely related as shown by aligned VH
and VL CDR3 sequences (Fig. 1B).
To confirm selectivity and to determine the binding
characteristics of the scFv-Ps isolated, each was amplified,
concentrated and titred in ELISA using insect cell derived
PrPc29–156-GFP, GFP and non-infected insect cell extract as
immobilised antigens (Fig. 2). CA22 and CA549 both displayed
typical antibody saturation binding curves, while CA328 and
CA330 displayed atypical linear binding that failed to reach
saturation even with highly concentrated phage stocks. None of
the scFv-Ps reacted with mock infected insect cell extracts or
GFP while a GFP MAb control confirmed immobilisation of
PrPc29–156-GFP to the suport (Supplementary Fig. 3). When
normalised to the same titre (1010 pfu/ml), the relative binding
order was CA22≫ CA549>CA328=CA330 (Supplementary
Fig. 3). A single scFv-P picked at random from the library and
treated identically to those isolated showed no binding to any
test antigen.encoding residues 29–156, was expressed in E. coli and purified and refolded as
thetic VH+VL scFv phage display library. A sample of∼2 μg was removed from
to markers with molecular weights as shown. (B) Sequence alignment of heavy
racterised, CA22, CA328, CA330 and CA549, all of which specifically recognise
Fig. 2. Antibody reactivity of isolated scFv-Ps. Phage isolated by the panning procedure using isolated PrPc29–156 fragment were assayed by ELISA against
baculovirus infected insect cell lysates expressing (i) PrPc29–156-GFP (▴), (ii) GFP (■) and (iii) control insect cell extract (♦). Phage identity is shown at the top left of
each panel. All values shown are the average of duplicates, and the bars represent the standard deviation. The initial phage titre was 1010 pfu/ml.
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The combination of two different sources of the same
PrPc fragment (residues 29–156) as bait and screen ensured
the isolation of CA22, CA328, CA330 and CA549 which
are specific to the N-terminal half of PrPc. To further define
the sequences recognised, limited epitope mapping was
done using a series of N-terminally truncated PrPc fusion
proteins PrPc37–156-GFP, PrP
c
48–156-GFP, PrP
c
68–156-GFP and
PrPc76–156-GFP, expressed and characterised in insect cells (Yao
et al., 2003). In order to provide comparative binding data,
ELISAs using the same PrPc protein extracts were also done
with a panel of monoclonal antibodies with epitopes previously
mapped to the amino-central region of PrPc, viz, 8B4, 11G5,
7H6, 7A12 (Li et al., 2000) and 6H4 (Korth et al., 1997)
(Supplementary Fig. 4). By ELISA, immobilisation of the
coating antigen was confirmed by binding a GFPMAb and each
scFv-P was found to bind to all the N-terminally truncated PrPc-
GFP proteins broadly equivalently to the PrPc29–156-GFP used
in their initial isolation (Fig. 3). Surprisingly, however, while
recognition of antigen by 8B4 (positive for PrP29–156-GFP and
PrP37–156-GFP) was consistent with the location of the mappedFig. 3. Phage and MAb ELISA reactivity with N-terminal truncations. ELISA used b
(♦), (ii) PrPc29–156-GFP (∇), (iii) PrPc37–156-GFP (X), (iv) PrPc48–156-GFP (★), (v)
shown at the top left of each panel. Phage were present in the assay at up to 1010 pfu/m
35–45 (8B4), 115–130 (11G5), 130–140 (7H6), 143–155 (7A12) and 144–152 (6H
standard deviation. The initial phage titre was 1010 pfu/ml.epitope between residue 35 and 45 (Li et al., 2000; Pan et al.,
2002), MAbs 11G5, 7H6, 7A12 and 6H4, all of which had
epitopes published within each expressed PrPc fragment (cf.
Supplementary Fig. 4), failed to bind significantly to any of the
truncated PrPc-GFP proteins (Fig. 3). To assess if such
differential binding between the scFv-Ps and characterised
MAbs was also apparent on denatured antigen, Western blots
were done using phage and antibody using the same fusion
proteins resolved by SDS-PAGE and transferred to PVDF
membranes. While all scFv-Ps bound each denatured antigen,
the pattern of binding was slightly different when compared to
the ELISA data (Fig. 4). CA22, CA330 and CA549 bound to all
truncated PrPc fragments strongly, while CA328 showed
stronger binding to PrPc29–156-GFP, PrP
c
37–156-GFP and
PrPc48–156-GFP than to PrP
c
68–156-GFP and PrP
c
76–156-GFP.
By contrast, and paralleling the ELISA data, MAb 8B4 blotted
the appropriate PrPc-GFP fusion proteins very effectively while
MAbs 11G5, 7H6, 7A12 and 6H4 failed to bind significantly
under identical conditions (Fig. 4). Thus, while both the new
scFv-Ps and published MAbs recognised linear epitopes
between PrPc amino acid 76 and 156, the efficiency of epitope
recognition was affected by the extent of surrounding PrPcaculovirus infected insect cell lysates expressing (i) a control baculovirus extract
PrPc68–156-GFP (○) and (vi) PrP
c
76–156-GFP (□). Antibody or phage identity is
l and MAbs at concentrations up to 1 μg/ml. Epitopes for the MAbs in use were
4). All values shown are the average of duplicates, and the bars represent the
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Fig. 4. Phage and MAb Western blot reactivity with N-terminal truncations.
Extracts of insect cells expressing the same PrPc-GFP fusion proteins as
described in Fig. 4 were resolved by SDS-PAGE and subject toWestern blot. The
lanes are: (1) GFP, (2) PrPc29–156-GFP, (3) PrP
c
37–156-GFP, (4) PrP
c
48–156-GFP,
(5) PrPc68–156-GFP and (6) PrP
c
76–156-GFP. The identity of the blotting scFv-P or
MAb is indicated. Molecular weights in kDa (top panel) apply to all.
170 C.S. Adamson et al. / Virology 358 (2007) 166–177sequence. Binding by several established MAbs to the PrPc-
GFP fusions used in these assays was distinctly weak or absent
under conditions where strong binding was evident by the
isolated scFv-Ps.
Antibody and scFv-P binding to full-length and C-terminally
truncated PrPc
Next, we assessed if the differential binding pattern exhibited
by scFv-Ps and MAbs on the same N-terminally truncated PrPc
fragments was also the case on full-length and C-terminally
truncated PrPc expressed in the same way. Phage scFvs and
MAbs were used in ELISA and Western blots on insect
cell extracts containing PrPc23–231-GFP, the full-length
extracellular PrPc sequence and on several C-terminally
truncated PrPc fragments, PrPc23–169-GFP, PrP
c
23–195-GFP
and PrPc23–216-GFP. All fusion proteins begin at the mature
PrPc amino terminus, residue 23, but have endpoints at residue
169, the end of the antiparallel β-sheet, at residue 195, the end
of the second α-helix and at residue 216 beyond the cysteine
residue in helix 3 involved in the single PrPc disulfide bond.
Each has been previously characterised as abundantly and
stably expressed in insect cells (Yao et al., 2003). In addition,
for this analysis, an additional antibody, MAb 8H4 recognising
residues 175–185 within the second α-helix (Zanusso et al.,
1998), was included to assess the accessibility of more
C-terminal epitopes within the target PrPc antigen.Fig. 5. Phage and MAb ELISA reactivity with full-length PrPc and C-terminal trun
infected cell lysates expressing (i) a control insect cell extract (♦), (ii) GFP (▪), (iii)
PrPc23–231-GFP (○). Antibody or phage identity is shown above each panel. Epitope
(8H4). All values shown are the average of duplicates, and the bars represent the st
markers, see Supplementary Fig. 2.Antibodies 8B4, 11G5, 7H6, 7A12, 6H4 and 8H4 all
efficiently recognised the full-length protein PrPc23–231-GFP
in ELISA as expected of a group of antibodies whose
collective epitopes span PrPc amino acids 115–185 (Fig. 5).
Binding was apparent also for 3 of the 4 phage antibodies.
However, of those scFv-Ps that bound, the binding curves
were different when compared to their original characterisa-
tion on PrPc29–156-GFP. CA22 bound as well to the full-length
PrPc fusion protein as it did to each PrPc truncation (compare
Fig. 5 with Fig. 3). Similarly, CA330 displayed non-saturating
linear binding on the full-length PrPc-GFP fusion protein as it
had on the original N-terminal PrPc fragment (cf. Fig. 2). The
pattern for CA549, however, changed from the saturation
binding curve on PrPc29–156-GFP (Fig. 2) to non-saturating
linear binding on the full-length protein (Fig. 5). In addition,
CA328, which bound to all N-terminally truncated PrPc
fragments (cf. Fig. 3), failed to react with PrPc23–231-GFP by
ELISA (Fig. 5). When binding of the scFv-Ps and MAbs was
assessed on the C-terminally truncated PrPc proteins however,
MAbs recognising epitopes between residue 115 and 155, as
well as the more C-terminal MAb 8H4, failed to bind
significantly to any target protein despite the fact that all
proteins were recognised by the N-terminal specific MAb 8B4
(Fig. 5). Singularly among the scFv-Ps, CA328 failed to react
with any C-terminal truncation, as it had with the full-length
PrPc fusion. A similar pattern of reactivity was also apparent
in Western blots where 8B4 recognised all fusion proteins at
equivalent levels while all other MAbs failed to bind to the
same degree under the conditions used despite strong binding
to the full-length fusion protein PrPc23–231-GFP (Fig. 6). By
contrast, all the scFv phage bound to C-terminally truncated
PrPc proteins with a pattern of binding similar to that shown
on the full-length molecule PrPc23–231-GFP, although CA328
binding was somewhat reduced on PrPc23–169-GFP when
compared to the binding shown by the other 3 phage
antibodies, partly reflecting its lack of binding to any
C-terminal truncation in ELISA and the fact it was sensitive
to the extent of N-terminal truncation (cf. Fig. 4). These data
confirm the general observations obtained with N-terminally
truncated PrPc-GFP fusion proteins. MAbs whose epitopes
spanned amino acids 115–155 of PrPc bound well to full-
length PrPc but poorly to equivalent loadings (see Supple-
mentary Fig. 3) of the various C-terminal fragments of PrPc,
while a nearly reciprocal pattern of binding was observed for
the phage antibodies isolated directly on an N-terminal PrPc
fragment PrPc29–156.
Phage scFv binding to non-GFP fused PrPc fragments
The use of PrPc fragments fused to GFP and expressed in
insect cells provided an abundant and highly selective source ofcated GFP fusion proteins. Antibody reactivity in ELISA against baculovirus
PrPc23–169-GFP (▵), (iv) PrP
c
23–195-GFP (X), (v) PrP
c
23–216-GFP (□) and (vi)
s for the MAbs in use were as described in Fig. 4 with the addition of 175–185
andard deviation. The initial phage titre was 1010 pfu/ml. For molecular weight
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Fig. 6. Phage and MAb Western blot reactivity with full-length PrPc and
C-terminal truncated GFP fusion proteins. Extracts of insect cells expressing the
same PrPc-GFP fusion proteins as described in Fig. 6 with the omission of GFP
only were resolved by SDS-PAGE and Western blotted. The lanes are: (1)
PrPc23–169-GFP, (2) PrP
c
23–195-GFP, (3) PrP
c
23–216-GFP and (4) PrP
c
23–231-GFP.
The identity of the blotting scFv-P or MAb is indicated.
172 C.S. Adamson et al. / Virology 358 (2007) 166–177antigen for screening PrPc binding by the isolated scFv-Ps, but
the finding that truncated PrPc fragments (either the amino or
carboxyl termini) fused to GFP altered reactivity to known
antibody binding sites when compared to the full-length protein
led us to carry out control binding assays with selected PrPc
fragments expressed in E. coli but not fused to GFP. Without
fusion, many PrPc fragments failed to refold successfully but
fragments akin to the fragment used for the original panning and
encoding residues 23–169 and 29–169 as well as full-length
PrPc residues 23–231 (Wong et al., 2000) could be expressed
and purified to near homogeneity and were quantified by direct
gel visualisation prior to use (Supplementary Fig. 5). When
immobilised in immunoassay plates, comparative binding of the
scFv-Ps and MAbs to these antigens showed that all scFv-P
bound to both the full-length PrPc and truncated fragments
although with varying efficiency (Fig. 7). Fragment 29–169
was recognised efficiently by all scFv-Ps with fragment 29–
156, the panning bait antigen, the next best recognised with the
exception of CA330 which preferentially bound the full-length
molecule 23–231. Recognition of 23–169 was the poorest
despite being only 6 residues larger than the best recognised
fragment. For the MAbs, 8B4 (residues 35–45) bound all
antigens at approximately equivalent levels but all other MAbs
bound only to the full-length PrPc molecule 23–231. As was the
case for truncated PrPc fragments fused to GFP, differences in
binding non-fused PrPc fragments evident by ELISA were
accentuated byWestern blot (Fig. 8). All scFv-Ps bound all PrPc
fragments, as did 8B4, similar to the ELISA data (cf. Fig. 7).
However, the remaining MAbs failed to bind or bound very
weakly (11G5) to any truncation, although each bound well to
the full-length molecule 23–231 (Fig. 8, lane 1). Therefore,
epitope exposure in the central domain of PrPc is powerfully
influenced by the extent of PrPc surrounding sequence. WhileFig. 7. Phage andMAb ELISA reactivity with non-fused PrPc fragment expressed and
fragments PrPc29–169 (▪), PrPc29–156 (♦), PrPc23–169 (▴) and PrPc23–231 (X). Antibody
use were as described in Figs. 4 and 6. All values shown are the average of duplicabinding to full-length PrPc either as a fusion protein or alone
was demonstrated by all MAbs used in this study, reaction with
approximately equimolar amounts of truncated PrPc molecules
was poor and was not the result of fusion protein use. In
addition, four scFv-Ps isolated in this study through purposeful
selection using a fragment of PrPc demonstrated significantly
different binding profiles when compared to the pre-existing
MAbs under identical conditions.
Discussion
The generation of prion antibodies was restricted originally
because of immunotolerance (Polymenidou et al., 2004).
However, using prion knockout mice, hypersensitisation and
in vitro antibody selection techniques, many antibodies have
since been isolated that react with a variety of PrPc species
(Arbel et al., 2003; Demart et al., 1999; Rubenstein et al., 1999;
Williamson et al., 1996, 1998; Zanusso et al., 1998). When
summed, however, there is a paucity of antibodies to the amino
terminal half of PrPc, presumably due to its unstructured nature.
Yet the antibodies that exist to this region appear to be
informative for probing both the native and disease isoforms of
PrPc. Leclerc et al., reported the innate propensity of
immobilised recombinant PrPc to undergo structural rearrange-
ments through antibody probing of the region between residue
90 and 115 (Leclerc et al., 2001). Using similar techniques, they
later reported the existence of several distinct and co-existing
PrPc subspecies on the cell surface (Leclerc et al., 2003). When
used to cross-link PrPc on the neuronal cell surface, MAbs D13
and P, recognising residues 95–105, but not MAb D18
recognising residues 133–157, induced apoptosis (Solforosi et
al., 2004), suggesting a key role for the amino-central sequences
in PrPc dependent signalling. Similarly synthetic IgGs shown to
be specific for the PrPSc isoform contain residues 89–112
(Moroncini et al., 2004) and react with some monomers within
fibrils generated from recombinant PrPc (Novitskaya et al.,
2006). These studies confirm that the wild type prion protein is
structurally enigmatic and requires further conformational
study. To aid this, we sought to isolate additional scFv-Ps to
the amino terminal half of PrPc. A targeted approach was
possible through the finding that residues 29–156 of PrPc could
be well expressed in insect cells (Yao et al., 2003), a result that
was also true following expression of this sequence as a non-
fused protein in E. coli (this work). Using phage display and a
screening strategy that alternated two sources of the same PrPc
sequence, we isolated four different phage, CA22, CA328,
CA330 and CA549, that recognised PrPc sequences between
residue 76 and 156. Further discrimination between the scFv-Ps
was possible by comparison between them and several existing
monoclonal antibodies. CA22 and CA549 had a higher affinity
for PrPc than did CA328 and CA330. CA328 was further
distinguished by reactivity dependent on the source of antigen
used for binding. By ELISA, CA328 binding to PrPc was lostpurified from E. coli. Antibody reactivity in ELISA against purified and refolded
or phage identity is shown in the top left of each panel. Epitopes for the MAbs in
tes, and the bars represent the standard deviation.
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Fig. 8. Phage and MAb Western blot reactivity with non-fused PrPc fragment
expressed and purified from E. coli. Western blot reactivity was identified by
the appropriate conjugate and chemiluminescence. The lanes are 1—PrPc23–231;
2—PrPc29–156; 3—PrP
c
29–169; 4—PrP
c
23–169. The identity of the blotting
scFv-P or MAb is shown. The top two panels on the left act as quantitation
controls and show the stained gel and Western blot using a His tag MAb
respectively (see also Supplementary Fig. 5). Molecular weights in kDa (top
left panel) apply to all.
174 C.S. Adamson et al. / Virology 358 (2007) 166–177when the first amino acid of the expressed sequence was shifted
to residue 23 whereas binding by CA22, CA330 and CA549
was unaffected. By Western blot, CA328 binding was main-
tained on all constructs but the strength of binding declined
with truncation of the amino terminus while, again, CA22,
CA330 and CA549 reactivity remained unaltered. CA328 was
also the only scFv-P whose reactivity in ELISAwas sensitive to
C-terminal truncation of PrPc sequence (Fig. 5), although this
was much less apparent on denatured antigen. Collectively these
data suggest that the four scFv-Ps do not recognise the same
epitope and when compared with a number of available PrPc
specific MAbs, the binding properties of the isolated scFv-Ps
appear to be novel. Under standard ELISA and Western blot
conditions, a number ofMAbs (11G5, 7H6, 7A12 and 6H4) with
defined epitopes within residues 115–155 reacted with full-
length PrPc but not with equivalent amounts of PrPc fragments
truncated at either the amino or carboxyl termini and assayed in
the same way. By contrast, MAb 8B4, recognising amino
terminal residues 35–45, showed a pattern of binding consistent
with the location of its epitope. Loss of MAb binding was not
related to the use of PrPc-GFP fusion proteins as the binding
differences were also observed using selected PrPc fragments
purified from E. coli. Together, our data suggest that (1) the
epitopes of the scFv-Ps isolated here are likely new as they do
not directly compete for the epitopes of 11G5, 7H6, 7A12 or
6H4 and (2) epitope exposure within the central region of PrPcis strongly influenced by the endpoints of the PrPc sequence
used as antigen. The epitopes of the MAbs used were mapped
previously using truncated PrPc molecules or peptides (Li et al.,
2000; Pan et al., 2002), but side-by-side experiments with full-
length protein to show the relative strength of binding were not
reported. Plausibly, in our truncated constructs, PrPc fragments
may adopt the structure of full-length PrPc that is usually only
apparent with time (PrPc “ageing” (Brown et al., 2000)) and
which showed substantially reduced antibody binding by D13
and 3F4 (residues 96–104 and 109–112 respectively) (Leclerc
et al., 2001). Consistent with this interpretation, MAb binding
by more N-terminal MAbs E123 and E149 (epitopes 29–37 and
72–86 respectively) was, like the binding data obtained here
with 8B4, relatively well preserved during the aging process
(Leclerc et al., ibid). With the exception of some binding by
CA328, scFv-P binding was observed on full-length PrPc as
well as all PrPc truncations. When compared with existing
MAbs with epitopes spanning residues 116–186, this would be
consistent with the scFv-P epitopes lying within residues 76–
115 and that this region is exposed within whatever structure
truncated PrPc molecules adopt. This prominence would
explain the fact that 4 scFv-Ps, although different, were all
isolated to this region during the panning reactions despite a bait
fragment that was far larger (residues 29–156). Interestingly,
this region encompasses one of the surfaces capable of specific
recognition of PrPSc (89–112) (Moroncini et al., 2004) and also
revealed when recombinant PrPc is induced to form amyloid
fibrils (Novitskaya et al., 2006). Our data confirm and extend
observations on the remarkable plasticity of PrPc and add new
reagents with which to probe it. In particular, use of the scFv-Ps
described here allowed us to conclude that known epitopes that
are well presented in the context of the complete PrPc become
occluded when either the amino or carboxyl terminus is
truncated. This observation extends our previous conclusion
that the unstructured N-terminus of PrPc may interact with
the structured C-terminal domain (Yao et al., 2003). It also
suggests that it is premature to conclude that the known three
dimensional structures of PrPc, residues 120–231, is the only
structure adopted by the physiologically relevant full-length
molecule. As the generation of Abs to discrete conformations of
PrPc is both desirable and complex (Korth et al., 1999), phage
display combined with discrete fragments of PrPc expressed in
different backgrounds may provide access to Abs with distinct
properties when compared to traditional immunisation. The
biological purpose of a molecule that has clearly been selected
during evolution (Rivera-Milla et al., 2003; van Rheede et al.,
2003; Wopfner et al., 1999) yet exhibits such extreme intrinsic
flexibility remains perplexing.
Materials and methods
Cell lines
E. coli TG1 (Hoogenboom et al., 1991) was used for the
propagation of phagemid and production of phage particles.
Prion protein was expressed in E. coli strain BL21 DE3 (pLysS)
(Novagen) using T7 driven expression and in Spodoptera
175C.S. Adamson et al. / Virology 358 (2007) 166–177frugiperda insect cells following infection by recombinant
baculoviruses. Sf 9 cells were cultured in SF900-II (Life
Sciences) at 28 °C.
Recombinant baculoviruses and E. coli plasmid expression
construct
A series of recombinant baculoviruses expressing various
fragments of the mouse short incubation PrPc amino terminus
fused to green fluorescent protein (GFP) has been described
elsewhere (Yao et al., 2003). Regions of PrPc were 23–231 (the
complete ectodomain), C-terminal truncations 23–169, 23–195,
23–216 and N-terminal fragments 29–156, 37–156, 48–156,
68–156 and 76–156. Based on the level of fluorescence and
SDS-PAGE analysis, fragment 29–156 was found to be well
expressed (Yao, et al., ibid) and was used to create an E. coli
expression plasmid encoding the same sequence without fusion
to GFP. Similarly, fragments 23–231, 23–169 and 29–169 were
expressed as untagged proteins in E. coli. A diagrammatic
representation of all the constructs used aligned with the known
features of the prion open reading frame and using the mouse
prnp a sequence as standard is available in Supplementary Fig. 1.
Purification and refolding of PrP fragments expressed in
E. coli
To produce the prion protein fragment 29–156 used for the
panning assays and other fragments for use in ELISA and
Western blot, inclusion bodies (IBs) that accumulated following
induction of T7 promoter driven expression in BL21 DE3
(pLysS) were prepared by a modified differential solubility
regime (Chan et al., 1997) and washed repeatedly with 1%
Triton X-100 until the purity of the IBs was at least 90% as
judged by SDS-PAGE. Purified IBs were denatured and
reduced at 95 °C for 5 min in a solution of 4 M urea, 10 mM
dithionite sulphate and 20 mM DTT and then clarified by
ultracentrifugation. Refolding of the protein was initiated by a
single 8× dilution step into a buffer containing 50 mM Tris·HCl
(pH 8.1), 1 mM KCl and 2 mM MgCl2 and incubated at 20 °C
for 3 h (Reid and Flynn, 1997). The solution was clarified and
used without further treatment.
Preparation of insect whole cell lysates expressing PrPc-GFP
proteins
PrPc-GFP proteins were expressed in Sf9 cells and harvested
48 h post infection. Cells were resuspended in PBS, sonicated
for 1.5 min and stored in aliquots at −80 °C. The PrPc-GFP
expression level within each lysate was assessed by SDS-PAGE
and Western blot (Supplementary Fig. 2).
Phage display library screening with PrPc29–156
The Griffin.1 human synthetic VH+VL scFv phage display
library (Griffiths et al., 1994) (scFv-P) was sourced from the
MRC Centre for Protein Engineering, Cambridge, UK. Panning
used an aliquot of the library representing 1012–13 phage dilutedin PBS containing 2% w/v milk block (M-PBS) on refolded
PrPc29–156 coated to an immunotube (Nunc) at ∼10 μg/ml. The
binding phase was 30 min with shaking followed by static
incubation for a further 2 h. Removal of unbound phage and
isolation of those retained were done as described (Hoogenboom
et al., 1991). Four rounds of panning were done, and individual
colonies (n=∼1000) were then picked using a Genetix colony
picking robot.
Propagation of scFv phage stocks
Positive individual bacterial colonies from each round of
selection were grown to mid log phase and infected with the
helper phage M13K07 and grown overnight at 30 °C in 40 ml of
2× TY containing ampicillin (100 μg/ml) and kanamycin
(25 μg/ml). Phage were precipitated from the supernatant by the
addition of 1/5th volume of PEG 6000 (20% w/v) and NaCl
(2.5 M) and incubation on ice for at least 1 h. Precipitated phage
were resuspended in 2 ml of PBS, titred and stored at 4 °C.
ELISA
Microtitre plates (Thermo Labsystems) were coated with Sf 9
whole cell lysates previously normalised for PrPc-GFP expres-
sion level by SDS-PAGE and Western blot (see (Yao et al.,
2003)), blocked with PBS-T, 5% dried milk powder and used
immediately. Despite normalisation, the coating efficiency as
determined by the binding of control antibodies to the GFP
domain differed slightly presumably due to varying efficiencies
of surface immobilisation. However, such variation did not
materially alter the data obtained for comparative MAb or scFv-
P binding to PrPc sequences. Primary antibodies were either
PEG precipitated phage (normalised to 1010 pfu/ml) or mouse
monoclonal antibodies (1 μg/ml) and were incubated with
antigen for 90 min at room temperature. Unbound phage or
antibody was removed by washing five times with PBS
containing 0.05% v/v Tween-20, and HRP-conjugated second-
ary antibody, either anti-M13 (1:5000, Pharmacia) or anti-
mouse (1:1000, Chemicon), was added for 1 h at room
temperature. The plate was washed extensively and incubated
with 3,3′,5,5′-Tetramethylbenzidine (TMB) chromagenic sub-
strate (Europa Bioproducts). The reaction was stopped by
addition of an equal volume of 0.5 M HCl, and absorbance was
read at 420 nm.
Screening antibody diversity
DNA fingerprinting and sequencing were used to monitor
PrP positive binding phage encoding diverse scFv antibody
fragments. The scFv encoding region of the phagemid was
amplified by PCR and digested with AluI or BstNI restriction
enzymes (Griffiths et al., 1994; Hoogenboom et al., 1991).
The resulting digests were resolved by 2% w/v agarose gel
electrophoresis, and those clones with different restriction
patterns were subjected to DNA sequencing. Derived heavy
and light chain sequences were aligned using Vector NTI
(Invitrogen).
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Protein samples were separated on pre-cast 10% Tris·HCl
SDS-polyacrylamide gels (BioRad) and transferred to Immobi-
lion-P membranes (Millipore) using a semi-dry blotter. Filters
were blocked for 1 h at room temperature using PBS containing
0.1% v/v Tween-20 (PBS-T), 5% w/v milk powder. Primary
antibody MAbs were used at 1 μg/ml, and phage of equivalent
titre were used at a dilution of 1:100 in PBS-T, 5% w/v milk
powder. Following several washes with PBS-T, the membranes
were incubated for 1 h with HRP-conjugated anti-mouse
(Chemicon) or anti-M13 (Pharmacia) antibody respectively
and bound antibodies detected by BM chemiluminescence
(Roche).
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